Horizon Kinetics Medical ETF

Horizon Kinetics Medical ETF Stock Forecast & Price Prediction

Live Horizon Kinetics Medical ETF Stock (MEDX) Price
$29.40

0

Ratings

  • Buy 0
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$29.40

P/E Ratio

18.42

Volume Traded Today

$3,701

Dividend

$1.38

52 Week High/low

32.00/27.32

Horizon Kinetics Medical ETF Market Cap

$17.23B

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $MEDX ๐Ÿ›‘

Before you buy MEDX you'll want to see this list of ten stocks that have huge potential. Want to see if MEDX made the cut? Enter your email below

MEDX Summary

Based on ratings from 0 stock analysts, the Horizon Kinetics Medical ETF stock price is expected to decrease by 100% in 12 months. This is calculated by using the average 12-month stock price forecast for Horizon Kinetics Medical ETF. The lowest target is $ and the highest is $. Please note analyst price targets are not guaranteed and could be missed completely.

MEDX Analyst Ratings

Horizon Kinetics Medical ETF has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that Horizon Kinetics Medical ETF will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.

MEDX stock forecast by analyst

These are the latest 20 analyst ratings of MEDX.

Analyst/Firm

Rating

Price Target

Change

Date


Truist Securities

Hold


Maintains

Jun 22, 2022

HSBC

Hold


Initiates

Nov 23, 2021

RBC Capital

Sector Perform


Maintains

Nov 17, 2021

Jefferies

Hold


Upgrade

Nov 11, 2021

SunTrust Robinson Humphrey

Buy


Maintains

May 21, 2020

SunTrust Robinson Humphrey

Buy


Maintains

May 11, 2020

SunTrust Robinson Humphrey

Buy


Maintains

Apr 13, 2020

CFRA

Buy


Upgrade

Feb 21, 2020

Jefferies

Buy


Upgrade

Jan 21, 2020

Redburn

Neutral


Downgrade

Oct 23, 2019

BTIG

Neutral


Downgrade

Aug 1, 2019

Barclays

Overweight


Upgrade

Jun 20, 2019

UBS

Buy


Upgrade

Oct 26, 2018

DZ Bank

Hold


Downgrade

Oct 18, 2018

HSBC

Buy


Upgrade

Aug 28, 2018

Deutsche Bank

Buy


Upgrade

Apr 24, 2018

Nomura

Buy


Initiates

Mar 17, 2016

UBS

Buy


Upgrade

Jan 5, 2016

SunTrust Robinson Humphrey

Buy


Maintains

Oct 30, 2015

PiperJaffray

Neutral


Maintains

Oct 30, 2015

MEDX Company Information

What They Do: An actively-managed ETF focused on medical industries.

Business Model: The fund generates revenue by actively investing at least 80% of its net assets in equity securities of companies involved in medical research, pharmaceuticals, and medical technology. By targeting both U.S. and foreign companies, it seeks to capitalize on growth opportunities within these sectors.

Other Information: Being non-diversified, the fund's performance heavily relies on a concentrated portfolio within the medical field, which may lead to higher volatility but also greater potential returns.
MEDX
Horizon Kinetics Medical ETF (MEDX)

When did it IPO

2023

Staff Count

0

Country

United States

Sector/Industry

/

CEO

Market Cap

$17.23B

Horizon Kinetics Medical ETF (MEDX) Financial Data

In 2023, MEDX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that MEDX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$17.86B

Revenue From 2021

$17.62B

-1.35 %
From Previous Year

Revenue From 2022

N/A

0.00 %
From Previous Year

Revenue From 2023

N/A

0.00 %
From Previous Year
  • Revenue TTM $17.62B
  • Operating Margin TTM 10.9%
  • Gross profit TTM $5.08B
  • Return on assets TTM 2.8%
  • Return on equity TTM 9.9%
  • Profit Margin 28.8%
  • Book Value Per Share 19.92%
  • Market capitalisation $17.23B
  • Revenue for 2021 $17.62B
  • Revenue for 2022 N/A
  • Revenue for 2023 N/A
  • EPS this year (TTM) $1.66

Horizon Kinetics Medical ETF (MEDX) Latest News

News Image

Wed, 01 May 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - Eli Lilly raised its 2024 outlook due to strong sales growth of its new obesity drug Zepbound and diabetes treatment Mounjaro.

Why It Matters - Eli Lilly's raised outlook signals strong revenue growth potential, driven by Zepbound and Mounjaro sales, likely boosting investor confidence and stock performance.

News Image

Wed, 07 Feb 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - Eli Lilly (LLY) reported strong Q4 2023 earnings, surpassing estimates due to high sales in diabetes and weight-loss treatments.

Why It Matters - Eli Lilly's strong earnings beat signals robust demand for its diabetes and weight-loss drugs, potentially driving stock growth and investor confidence in future performance.

News Image

Fri, 03 Nov 2023

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - Eli Lilly (LLY) reported strong Q3 2023 earnings, surpassing estimates for revenue and profit, with continued strong performance from its Mounjaro anti-obesity drug.

Why It Matters - Eli Lilly's strong earnings and Mounjaro's success indicate financial health and growth potential, positively influencing investor sentiment and stock performance.

News Image

Wed, 09 Aug 2023

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - Eli Lilly's stock surged significantly after a strong Q2 2023 earnings report and positive outlook, making ETFs with high exposure to the company attractive for investors.

Why It Matters - Eli Lilly's stock surge signals strong financial performance and growth potential, making related ETFs attractive for capitalizing on this momentum.

News Image

Tue, 20 Jun 2023

Sentiment - POSITIVE

Source - GuruFocus

Summary - The Oakmark Intl Small Cap Fund updated its portfolio for the quarter ending March 31, with the fiscal year concluding in September.

Why It Matters - The Oakmark Intl Small Cap Fund's portfolio updates signal shifts in investment strategy, potentially impacting market trends and investor sentiment in small-cap equities.

News Image

Wed, 21 Jun 2023

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - Eli Lilly (LLY) will acquire DICE Therapeutics (DICE) for about $2.4 billion to enhance its immunology pipeline for immune disease treatments.

Why It Matters - Eli Lilly's acquisition of DICE Therapeutics enhances its immunology portfolio, potentially leading to increased market share and revenue from new treatments for immune diseases.

...

MEDX Frequently asked questions

The highest forecasted price for MEDX is $ from at Jefferies.

The lowest forecasted price for MEDX is $ from from Jefferies

The MEDX analyst ratings consensus are 0 buy ratings, 0 hold ratings, and 0 sell ratings.